Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;25(4):304-8.
doi: 10.1097/MOL.0000000000000092.

Apolipoprotein A-I mimetics

Srinivasa T Reddy  1 , Mohamad Navab, Gattadahalli M Anantharamaiah, Alan M Fogelman
Affiliations
Review

Apolipoprotein A-I mimetics

Srinivasa T Reddy et al. Curr Opin Lipidol. 2014 Aug.

Abstract

Purpose of review: To summarize recent publications in the field of apolipoprotein mimetics.

Recent findings: Apolipoprotein mimetic peptides continue to show efficacy in a number of animal models of disease and demonstrate properties that make them attractive as potential therapeutic agents. A number of new apolipoprotein mimetics have been described recently. A major site of action of apolipoprotein mimetic peptides was found to be in the small intestine in which they decrease the levels of proinflammatory bioactive lipids. A major problem related to the use of apolipoprotein mimetic peptides is their cost, particularly those that need to be generated by solid phase synthesis with chemical addition of end-blocking groups. Novel approaches to apolipoprotein mimetic therapy have emerged recently that show promise in overcoming these barriers.

Summary: Despite the recent failure of therapies designed to raise HDL-cholesterol in humans, an approach to therapy using mimetics of HDL and its components continues to show promise.

PubMed Disclaimer

References

    1. Lüscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: Vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014;114:171–182. This review puts into perspective the recent clinical trials aimed at raising HDL-cholesterol levels. - PubMed
    1. Reddy ST, Navab M, Anantharamaiah GM, Fogelman AM. Searching for a successful HDL-based treatment strategy. Biochim Biophys Acta. 2014;1841:162–167. This review makes the case for pursuing an HDL-based treatment strategy despite the failure of the recent clinical trials aimed at raising HDL-cholesterol levels. - PubMed
    1. Navab M, Reddy ST, Van Lenten BJ, et al. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: Novel hypotheses and review of literature. Arterioscler Thromb Vasc Biol. 2012;32:2553–2560. - PMC - PubMed
    1. Kwon WY, Suh Gj, Kim KS, et al. 4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats. J Trauma Acute Care Surg. 2012;72:1576–1583. This study shows that an apoA-I mimetic peptide can be effective even after endotoxemia was established. - PubMed
    1. White CR, Smythies LE, Crossman DK, et al. Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F. Arterioscler Thromb Vasc Biol. 2012;32:2631–2639. This study demonstrates that apoA-I mimetic peptides can mediate macrophage responsiveness to pro-inflammatory signals by regulating TLRs. - PMC - PubMed

Publication types